7TM Pharma was developing obinepitide, a subcutaneously administered dual neuropeptide Y (NPY) Y2 and Y4 receptors agonist, for the treatment of obesity. Obinepitide is a synthetic analogue of two natural human hormones, PYY and Pancreatic Polypeptide, which normally are released during a meal. These hormones are known to play a role in the regulation of food intake and appetite in man as satiety signal from the GI-tract to the CNS. In obinepitide, the properties of both of these hormones have been implanted into a single molecule. Obinepitide targets the Y2 and Y4 receptors, with selectivity over the Y1 receptor, which is involved in causing cardiovascular side effects. Obinepitide inhibited food intake up to nine hours after dosing.